Bellerophon Therapeutics IncOver The Counter Market:BLPH
- LAST PRICE0.0550
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0550
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLPH |
|---|---|---|
| 01:11 ET | 110 | 0.038 |
| 01:40 ET | 100 | 0.055 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bellerophon Therapeutics Inc | 672.8K | -0.1x | --- |
Point of Care Nano-Technology Inc | 726.9K | 0.0x | --- |
NovAccess Global Inc | 594.3K | -0.1x | --- |
PaxMedica Inc | 761.5K | 0.0x | --- |
Capstone Therapeutics Corp | 504.4K | -0.5x | --- |
TC Biopharm (Holdings) PLC | 332.8K | 0.0x | --- |
Company Information
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Contact Information
- Headquarters
- 184 Liberty Corner Road, Suite 302WARREN, NJ, United States 07059
- Phone
- 908-574-4770
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Naseem Amin
- President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Company Secretary, Director
- Craig Jalbert
- Vice President - Regulatory Affairs and Quality Assurance
- Bobae Kim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $672.8K |
|---|---|
Revenue (TTM) | $5.6M |
Shares Outstanding | 12.2M |
Bellerophon Therapeutics Inc does not pay a dividend. | |
Beta | 0.79 |
EPS | $-0.84 |
Book Value | $0.26 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -195.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
